A study in 2017 demonstrated that HIF-1α causes an increase in the glycolysis pathway and pyrimidine synthesis, which is the mechanism of gemcitabine resistance in pancreatic cancer, and targeting HIF-1α can increase the effectiveness of gemcitabine (27). The gene discussed is HIF1A; the disease is familial pancreatic carcinoma.